What is HC Wainwright’s Forecast for WVE FY2026 Earnings?

WAVE Life Sciences Ltd. (NASDAQ:WVE) – Equities researchers at HC Wainwright issued their FY2026 earnings per share estimates for WAVE Life Sciences in a research report issued on Wednesday, October 28th. HC Wainwright analyst A. Ghosh anticipates that the company will earn ($1.09) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for WAVE Life Sciences’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for WAVE Life Sciences’ Q4 2026 earnings at ($0.31) EPS, Q1 2027 earnings at ($0.26) EPS, Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.28) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.79) EPS, FY2029 earnings at ($0.68) EPS and FY2030 earnings at ($0.47) EPS.

A number of other equities analysts have also commented on WVE. Wall Street Zen lowered WAVE Life Sciences from a “hold” rating to a “strong sell” rating in a research note on Saturday, August 1st. Leerink Partners set a $10.00 price objective on shares of WAVE Life Sciences in a research report on Tuesday. JPMorgan Chase & Co. initiated coverage on WAVE Life Sciences in a research note on Wednesday, September 23rd. They issued a “neutral” rating for the company. Wedbush set a $13.00 price target on shares of WAVE Life Sciences in a research note on Friday, October 2nd. Finally, Zacks Research cut WAVE Life Sciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $20.89.

WAVE Life Sciences Price Performance

NASDAQ WVE opened at $3.63 on Friday. The stock’s 50 day simple moving average is $4.10 and its 200 day simple moving average is $7.55. WAVE Life Sciences has a one year low of $3.04 and a one year high of $21.73. The firm has a market cap of $715.94 million, a PE ratio of -3.39 and a beta of -1.43.

WAVE Life Sciences (NASDAQ:WVE) last posted its earnings results on Tuesday, October 27th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.03. The business had revenue of $13.16 million for the quarter, compared to analyst estimates of $4.51 million. WAVE Life Sciences had a negative net margin of 296.86% and a negative return on equity of 44.66%.

Insider Transactions at WAVE Life Sciences

In other news, Director Heidi L. Wagner sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $6.01, for a total transaction of $42,070.00. Following the sale, the director owned 44,930 shares in the company, valued at $270,029.30. This represents a 13.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Adrian Rawcliffe sold 12,700 shares of the stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $5.29, for a total value of $67,183.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 23,564 shares of company stock valued at $132,476. Company insiders own 24.34% of the company’s stock.

Institutional Investors Weigh In On WAVE Life Sciences

Several hedge funds have recently bought and sold shares of the company. Readystate Asset Management LP bought a new position in shares of WAVE Life Sciences in the second quarter valued at about $27,465,000. Squarepoint Ops LLC raised its holdings in WAVE Life Sciences by 68.0% in the 2nd quarter. Squarepoint Ops LLC now owns 2,541,442 shares of the company’s stock valued at $14,766,000 after acquiring an additional 1,029,052 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in WAVE Life Sciences by 42.6% during the first quarter. Pictet Asset Management Holding SA now owns 1,149,127 shares of the company’s stock worth $8,202,000 after buying an additional 343,226 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of WAVE Life Sciences by 152.6% during the 1st quarter. Renaissance Technologies LLC now owns 597,220 shares of the company’s stock worth $4,330,000 after acquiring an additional 360,800 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of WAVE Life Sciences by 12.4% during the 1st quarter. Bank of New York Mellon Corp now owns 361,204 shares of the company’s stock worth $2,619,000 after buying an additional 39,759 shares in the last quarter. 89.73% of the stock is currently owned by institutional investors and hedge funds.

WAVE Life Sciences News Summary

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: Third-quarter results beat expectations: WAVE reported $13.16 million in revenue versus the $4.51 million consensus estimate and a loss of $0.30 per share, narrower than the expected $0.33 loss. The results helped reduce near-term concerns about the company’s financial performance. Wave Life Sciences Stock Rallies As Q3 Results Ease Loss Fears
• Positive Sentiment: HC Wainwright initiated coverage with a Strong-Buy rating: The firm’s forecasts call for losses of $1.09 per share in fiscal 2026 and fiscal 2027, narrowing to $0.79 in 2028, $0.68 in 2029 and $0.47 in 2030. The rating indicates confidence in WAVE’s longer-term potential despite continued projected losses. HC Wainwright WAVE Coverage
• Positive Sentiment: Additional bullish attention supported the rally: Reports highlighted WAVE among healthcare stocks viewed favorably by analysts, while separate coverage noted that the shares rose after the strong earnings release. Analysts Are Bullish on WAVE
• Neutral Sentiment: Oppenheimer remained constructive but reduced its price target: The firm lowered its target to $29 from $32 while maintaining an Outperform rating, creating a mixed signal for investors. Oppenheimer Adjusts WAVE Price Target
• Negative Sentiment: Profitability remains a significant risk: HC Wainwright expects WAVE to continue posting quarterly and annual losses through 2030. The company’s negative net margin and ongoing cash needs could limit the durability of the earnings-driven advance.

About WAVE Life Sciences

WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that act on RNA, a molecule involved in translating genetic information into proteins. The company uses its proprietary chemistry and drug-design technologies to create oligonucleotide therapeutics intended to selectively modify RNA and address the underlying causes of genetic diseases.

Its research programs have included RNA editing and RNA-targeting approaches for conditions such as alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other serious genetic disorders.